Miscellaneous photos/iStock Editorial via Getty Images
Medical Silk Road (NASDAQ:SILK) fell by 0.4% after a note that said the planned sale of the company to Boston Scientific (New York Stock Exchange:BSX) could be subject to a thorough antitrust review in the United States.
The deal could trigger a second request from the Federal Trade Commission, according to traders, who cited An article from Washington Analysis circulated Thursday. The companies overlap in treating carotid artery disease, which may prompt the regulator to request a more thorough review. It is also possible that the companies will withdraw the application and resubmit it to try to avoid a second application.
In June, Boston Scientific announced an agreement to acquire medical device company Silk Road Medical (SILK) for $27.50 per share, representing an enterprise value of approximately $1.16 billion.
Silk Road (SILK) announced its second quarter results on Wednesday.
